Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303184 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A Phase 2 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT02303184 is a Phase 2 study that has completed, run by Clearside Biomedical. The registered enrollment target is 46 participants.
The verdict
NCT02303184, a Phase 2 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given along with an intravitreal (IVT) injection of aflibercept compared to IVT aflibercept alone in subjects with retinal vein occlusion (RVO).
Interventions
- DRUG Sham
- DRUG 4 mg CLS-TA
- DRUG IVT aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02303184
The ClinicalTrials.gov registry entry for NCT02303184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham is the first listed.
NCT02303184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02303184 about?
NCT02303184 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO". A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given along with an intravitreal (IVT) injection of aflibercept compared to IV...
What is the current status of trial NCT02303184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2015-01. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02303184?
The interventions under investigation include: Sham (DRUG), 4 mg CLS-TA (DRUG), IVT aflibercept (DRUG).
Who is sponsoring clinical trial NCT02303184?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.